Showing 21–22 of 22 resultsSorted by latest
-
Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Price range: $6,989.00 through $20,967.00About 60% of ALL adult patients relapse or are refractory to first-line therapy and a high unmet need continues to exist. CD19 CAR T candidate with compelling activity and safety profile and has the potential to change the standard of care as a curative therapy for r / r ALL. Sales of emerging therapies to treat adult Acute Lymphoblastic Leukemia (aALL) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2022-2032 study period, adding an estimated value to a total more than $1 billion market by 2032
-
Acute Kidney Injury (AKI) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Price range: $6,989.00 through $20,967.00Growth of the incidence AKI population will contribute to increasing sales in the AKI therapy market over our forecast period. An estimated annual growth rate of 2.68% in the diagnosed incident AKI population across the major pharmaceutical markets will contribute to increasing AKI therapy sales. In 2019, there were approximately 1.95 million diagnosed cases of AKI in the major markets; we expect the number of cases will exceed 2 million in 2032 owing to changes in population demographics and increasing cases of AKI associated conditions such as sepsis-AKI, Cardiac surgery-associated AKI and others.
The continuous involvement of supportive treatments including renal replacement therapies for the management of AKI patients will contribute to the the overall growth of the AKI therapy market. We forecast that total sales of the total care market will reach $XX billion by 2032.
Product Search
Filter by price
Product categories
- Inflammatory 1
- Genetic Disorders 1
- Head and Neck Cancers 2
- Renal Diseases / Nephrology 6
- HER-Low Status in Cancer 4
- Endocrinology 1
- Artificial Intelligence 1
- Pipeline Analytics Report 3
- Pharma & Biotech 1
- Disease Competitive Landscape Monitoring 3
- Metabolic Disorders 1
- Therapeutic Area 24
- Musculoskeletal Diseases 1
- Oncology 7
- Hematology 3
- Market Forecast 22
- Respiratory Diseases 1
- Ophthalmology 1
- Orthopedics 1
- Central Nervous System 7